C1INH Activators
The chemical class of C1INH activators comprises compounds that indirectly affect C1INH function through their influence on complement activation, coagulation, and inflammation pathways. These compounds do not directly activate C1INH; instead, they modulate the biological processes and pathways in which C1INH is a key regulatory component. Compounds such as Eculizumab, which inhibits the complement protein C5, can reduce overall complement activation, potentially altering the regulatory demand on C1INH. Anticoagulants like Warfarin, Heparin, Rivaroxaban, Dabigatran, Apixaban, and Nafamostat impact various points in the coagulation cascade. By influencing these pathways, they may indirectly affect the role of C1INH in coagulation regulation. Similarly, antifibrinolytic agents like Tranexamic Acid, which inhibits plasminogen activation, can have implications for the coagulation system and, subsequently, for C1INH activity.
Moreover, anti-inflammatory agents like Ibuprofen, Prednisone, Dexamethasone, and Aspirin affect inflammation pathways. By modulating these pathways, these compounds can have an indirect impact on C1INH, given its involvement in inflammation regulation. These chemicals, through their diverse mechanisms of action, contribute to a cellular environment where the regulation and function of C1INH can be indirectly influenced.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Warfarin | 81-81-2 | sc-205888 sc-205888A | 1 g 10 g | $72.00 $162.00 | 7 | |
An anticoagulant that inhibits vitamin K epoxide reductase, potentially influencing coagulation pathways and indirectly affecting C1INH activity. | ||||||
Heparin | 9005-49-6 | sc-507344 | 25 mg | $117.00 | 1 | |
An anticoagulant that enhances antithrombin III activity, potentially influencing coagulation and indirectly affecting C1INH. | ||||||
Rivaroxaban | 366789-02-8 | sc-208311 | 2 mg | $155.00 | 18 | |
A direct factor Xa inhibitor, potentially influencing coagulation pathways and indirectly affecting C1INH activity. | ||||||
Dabigatran | 211914-51-1 | sc-481166 | 5 mg | $205.00 | 1 | |
A direct thrombin inhibitor, potentially impacting coagulation pathways and indirectly affecting C1INH regulation. | ||||||
Apixaban | 503612-47-3 | sc-364406 sc-364406A | 10 mg 50 mg | $235.00 $622.00 | 2 | |
Another direct factor Xa inhibitor, potentially impacting coagulation and indirectly influencing C1INH activity. | ||||||
Ibuprofen | 15687-27-1 | sc-200534 sc-200534A | 1 g 5 g | $52.00 $86.00 | 6 | |
A nonsteroidal anti-inflammatory drug (NSAID) that may influence inflammation pathways, potentially affecting C1INH regulation. | ||||||
Prednisone | 53-03-2 | sc-205816 sc-205816A sc-205816B | 1 g 5 g 25 g | $41.00 $133.00 $663.00 | 2 | |
A corticosteroid that modulates inflammation, potentially influencing C1INH activity indirectly through its effects on the immune system. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
Another corticosteroid, potentially affecting C1INH activity indirectly through its anti-inflammatory effects. | ||||||
Aspirin | 50-78-2 | sc-202471 sc-202471A | 5 g 50 g | $20.00 $41.00 | 4 | |
An NSAID that inhibits platelet aggregation, potentially influencing coagulation pathways and indirectly affecting C1INH. | ||||||
Nafamostat mesylate | 82956-11-4 | sc-201307 sc-201307A | 10 mg 50 mg | $80.00 $300.00 | 4 | |
A protease inhibitor that inhibits various enzymes in the coagulation cascade, potentially affecting C1INH activity. | ||||||